Working... Menu

A Study of the Efficacy and Safety of Intranasal Esketamine in the Rapid Reduction of Symptoms of Major Depressive Disorder, in Adult at Imminent Risk for Suicide (Aspire I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03039192
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : February 11, 2019
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 18, 2018
  Actual Study Completion Date : December 18, 2018